Pritumumab, CAS 499212-74-7

Product Description: Pritumumab is a natural human IgG1kappa mAb originally isolated from a regional draining lymph node of a patient with cervical carcinoma. Pritumumab recognizes vimentin expressing on the cell surface of the malignant tumor. Pritumumab can be used for glioblastoma research[1][2].

Applications: Cancer-programmed cell death

Formula: N/A

References: [1]Santosh Kesari, et al. Pritumumab binding to glioma cells induces ADCC and inhibits tumor growth. ASCO Annual Meeting I. 2017. /[2]Hugwil AV. The meaning of the anti-cancer antibody CLN-IgG (Pritumumab) generated by human × human hybridoma technology against the cyto-skeletal protein, vimentin, in the course of the treatment of malignancy. Med Hypotheses. 2013 Sep;81(3):489-95.

CAS Number: 499212-74-7

Molecular Weight: N/A

Compound Purity: 95.00

Research Area: Cancer

Solubility: H2O

Target: Others

• Artikelnummer: MEXHY-P99806-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99806-10
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Konjugat: Unconjugated